Clinical trial
An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors
NCT03028103 is registered in ClinicalTrials.gov with Epizyme, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors
- Lead sponsor
- Epizyme, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- March 27, 2017
- Completion date
- November 29, 2019
- Enrollment
- 32 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor, diffuse large b cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, primary mediastinal lymphoma